About Congenital Adrenal Hyperplasia
Congenital adrenal hyperplasia (CAH) comprises rare autosomal recessive disorders of cortisol and aldosterone synthesis resulting from enzymatic defects in the steroidogenic pathway. Over 90% result from deficiency of 21-hydroxylase (CYP21A2 gene mutations), with remaining cases due to 11-beta-hydroxylase, 3-beta-hydroxysteroid dehydrogenase, or lipoid CAH.
The 21-hydroxylase enzyme deficiency blocks cortisol synthesis at a critical step, causing shunting of precursors into androgen production, resulting in excessive androgens and combined glucocorticoid and mineralocorticoid deficiency. Three distinct clinical phenotypes exist: salt-wasting (most severe, presenting at 1-4 weeks with hyponatremia, hyperkalemia, and circulatory collapse), simple virilizing (androgen excess without salt wasting, manifesting at birth or early childhood), and non-classic (mild or late-onset androgen excess).
Newborn females with classic forms show external virilization including clitoromegaly, labial fusion, and potential ambiguous genitalia. Males may present with precocious puberty or salt-wasting crisis. Without treatment, salt-wasting CAH is life-threatening; all forms require lifelong hormone replacement and monitoring.
Common Symptoms of Congenital Adrenal Hyperplasia
Recognizing the signs of Congenital Adrenal Hyperplasia early can lead to faster diagnosis and better outcomes. Symptoms may vary in severity from person to person. If you or a loved one are experiencing any of the following, consider speaking with a specialist.
- Virilization in female newborns (female pseudohermaphroditism)
- Salt-wasting crisis in severe forms (hyponatremia, hyperkalemia)
- Precocious puberty and rapid growth in males
- Accelerated linear growth in childhood
- Acne and male-pattern baldness
- Infertility and reproductive dysfunction
Who Congenital Adrenal Hyperplasia Affects
CAH shows autosomal recessive inheritance, affecting males and females equally across all populations. However, prevalence varies significantly by ethnicity and geography: highest in populations from the Middle East, North Africa, and Hispanic heritage (1 in 15,000 in some populations); intermediate in Caucasians and African populations (1 in 10,000-25,000); lowest in East Asians.
Manifestations appear in neonates and early infants (salt-wasting forms) or early childhood (simple virilizing forms). Non-classic forms may present in adolescence or adulthood during reproductive years, particularly in females with irregular menses or hirsutism. Genetic counseling indicates 25% recurrence risk in subsequent pregnancies if both parents are identified carriers.
Find Your Next Step
FDA-Approved Treatments for Congenital Adrenal Hyperplasia
There are currently 3 FDA-approved medications for Congenital Adrenal Hyperplasia. These therapies represent the current standard of care and may be used alongside or compared against investigational treatments in active clinical trials.
Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.
Help Paying for Congenital Adrenal Hyperplasia Treatment
Charity funds and drugmaker programs for Congenital Adrenal Hyperplasia, checked at the source.
Side Effect Explorer
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Genetic Testing
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
Finding labs...
Trusted Congenital Adrenal Hyperplasia Resources
Reputable organizations and medical references for learning more about Congenital Adrenal Hyperplasia, including disease registries, foundation resources, and clinical guidelines.